Clinical Trial: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Brief Summary: This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the effect on the malignancy.

Detailed Summary:

Condition

Diverse malignancies either associated with or thought to be associated with activated tyrosine kinase enzymes including hypereosinophilic syndrome systemic mastocytosis chronic myelomonocytic leukaemia, dermatofibrosarcoma protuberans and other diseases.

Not included:

Patients with chronic myeloid leukemia, some other types of leukemias (abl-mutated) some types of gastrointestinal stromal tumours (c-KIT-positive), some systemic mastocytosis (if c-KIT D816V mutation), brain, prostate, breast or lung cancers.

Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: To assess the efficacy and the safety of imatinib mesylate therapy [ Time Frame: 2 years ]

Original Primary Outcome:

Current Secondary Outcome: To evaluate the effects of imatinib on quality of life and healthcare resource use [ Time Frame: 2 years ]

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: September 13, 2005
Date Started: September 2004
Date Completion:
Last Updated: February 21, 2017
Last Verified: February 2017